Sirolimus prescription requirements: what you actually need

Last updated 2026-07-27

Is sirolimus available without a prescription anywhere in the US?

No. Sirolimus is approved by FDA as Rapamune (oral solution and tablets) and is classified as a prescription-only drug under the Federal Food, Drug, and Cosmetic Act. There's no OTC version, no supplement version, and no legal gray zone like there is with, say, melatonin or certain peptides sold as "research chemicals." FDA's own label for Rapamune states it is indicated "for the prophylaxis of organ rejection in patients aged 13 years or older receiving renal transplants" ^[1]. Some vendors sell "rapamycin" as a research compound, unlabeled for human use, and technically outside FDA's drug enforcement reach because it's marketed "not for human consumption." That's a real gray market, and it's a bad idea. You have no idea what's actually in the vial, no pharmacist checking your kidney function or drug interactions, and no chain of custody if something goes wrong. If you want the real drug at a real dose, you need a prescription tied to a specific NDC number, filled by a licensed pharmacy. Sirolimus and rapamycin are the same molecule. Rapamycin is the generic chemical name (isolated from Streptomyces hygroscopicus soil bacteria found on Easter Island); sirolimus is the US Adopted Name used on the prescription label. Rapamune is the original Wyeth (now Pfizer) brand name. If a source tells you rapamycin doesn't need a prescription because it's not "sirolimus," that's marketing, not pharmacology.

What is sirolimus actually FDA-approved to treat?

FDA has approved sirolimus for three narrow uses, and longevity or anti-aging is not one of them. The original approval (1999) is for prophylaxis of organ rejection in kidney transplant patients, generally used with cyclosporine and corticosteroids ^[1]. The label carries a boxed warning about increased risk of infection and malignancy, especially lymphoma, from the immunosuppression itself ^[1]. The second approval is Fyarro (sirolimus protein-bound particles), approved by FDA in November 2021 for advanced malignant perivascular epithelioid cell tumor (PEComa), a rare soft-tissue cancer ^[2]. The third is Hyftor (topical sirolimus gel), approved for facial angiofibroma associated with tuberous sclerosis complex ^[3]. None of these approvals mention aging, lifespan, or healthspan. Every use for longevity, whether daily microdosing or the popular weekly pulse protocols discussed in the dosage literature, is off-label. Off-label prescribing is legal in the US; a physician can prescribe an approved drug for an unapproved use based on clinical judgment. What's not legal is a pharmaceutical company marketing it that way, which is why you won't find FDA guidance, a package insert, or an approved dose for "anti-aging use."

Why do you need a doctor for something with such strong mouse data?

Because mouse data, however strong, is not the same as a human safety or efficacy finding, and the FDA-required prescription barrier exists precisely for drugs like this: real biological effect, real risk profile, no completed human outcome trial to calibrate against. The strongest evidence for rapamycin extending lifespan comes from the National Institute on Aging's Interventions Testing Program (ITP), a multi-site, replicated study design. Rapamycin, started at 600 ppm in food at 9 months of age, extended median lifespan by 23% in male mice and 26% in female mice compared to controls in the original 2009 report ^[4]. Later ITP cohorts found benefits at doses as low as 14 ppm and even when started late in life (at 20 months), and the effect has now been replicated across multiple independent cohorts and dose levels ^[5]. That's about as good as animal aging data gets. But there is no completed randomized controlled trial testing whether rapamycin extends human lifespan or healthspan. The closest human data are small, short trials on surrogate markers: a 2014 study in elderly volunteers found that RAD001 (everolimus, a rapamycin analog) improved influenza vaccine response, suggesting immune benefits from mTOR inhibition , and a 2016-2019 PEARL trial (unpublished in full peer-reviewed form as of this writing, reported via conference and preprint data) looked at intermittent low-dose sirolimus in healthy adults for safety and biomarkers, not lifespan. Nobody has run, or completed, a trial that says "humans who took rapamycin for a decade lived longer." That gap is the whole story, and it's exactly why a prescriber, not a supplement aisle, sits between you and the drug.

What does a doctor need to check before prescribing sirolimus off-label?

A responsible prescriber for longevity-dose sirolimus should be running baseline labs and periodic monitoring, more than writing a script off a questionnaire. At minimum, this typically means a fasting lipid panel, fasting glucose or HbA1c, complete blood count, and kidney function tests before starting, because sirolimus's known human side effects (from the transplant literature, at much higher continuous doses) include hyperlipidemia, hyperglycemia, delayed wound healing, and mouth ulcers (stomatitis) ^[1]. Mouth ulcers are the single most common complaint in people using intermittent rapamycin protocols, reported anecdotally by a meaningful fraction of users and documented in the transplant-dose literature as a frequent adverse event tied to mTOR inhibition of epithelial cell turnover. They're usually manageable with dose adjustment or timing changes, but they're real and expected, not rare. Immunosuppression is the other non-negotiable risk conversation. Even at low, intermittent, weekly-pulse doses designed to spare some of the chronic immunosuppression seen in transplant patients, sirolimus is an mTOR inhibitor, and mTOR sits at the center of immune cell proliferation. A prescriber should ask about upcoming surgeries, live vaccines, active infections, and any immune-compromising conditions before starting, and should recheck labs periodically, more than once. If a service issues a prescription without any labs at all, that's a flag worth noticing, not a convenience worth celebrating.

How does someone actually get a legal sirolimus prescription for longevity use?

Three things need to line up: a licensed prescriber willing to write for off-label use, a pharmacy willing to fill it, and you being informed enough to monitor yourself between visits. In practice this happens through three channels. Traditional route: an internist, geriatrician, or interested primary care doctor who has read the ITP literature and is comfortable prescribing off-label with monitoring. This is still uncommon; most general practitioners have never prescribed sirolimus for anything and may be unfamiliar with the longevity dosing literature entirely. Longevity clinic route: specialty clinics built around off-label longevity prescribing (rapamycin, metformin, and similar agents) that combine the consult, labs, and prescription in one visit, often at a premium price. Telehealth route: online platforms that connect you with a licensed physician for an asynchronous or video consult, review your health history and sometimes labs, and if appropriate write a prescription filled by a partner pharmacy. This is where most longevity-dose sirolimus in the US actually gets prescribed today, because it solves the discovery problem (finding any doctor willing to prescribe it) without requiring you to find a specialty clinic in your city. Sirolimus Rx works this way: a licensed provider reviews your case, and if a prescription is appropriate, it's filled by a partner pharmacy, not compounded or shipped by Sirolimus Rx itself. Whatever route you use, the prescription still has to originate from a real clinical relationship, not a checkbox.

What dose and schedule will a prescriber typically write for?

For longevity use, most prescribers writing off-label sirolimus use intermittent, once-weekly dosing rather than the continuous daily dosing used in transplant medicine, based on the ITP's dose-response data and the theory that pulsed dosing may reduce chronic immunosuppression while preserving mTOR-inhibition benefits. Common off-label regimens cited in the longevity literature range from about 3 mg to 10 mg once weekly, adjusted by body weight, kidney function, and tolerance, though there is no FDA-approved dose for this use and no large human trial establishing an optimal number. Rapamune's own approved transplant dosing is a daily 6 mg loading dose followed by 2 mg daily, a completely different regimen built for continuous immunosuppression, not longevity ^[1]. Because the drug has a long half-life (roughly 57 to 63 hours in the approved label's pharmacokinetic data) ^[1], weekly dosing produces meaningful peak-and-trough variation, which is part of the rationale behind pulsing rather than daily use. If you're at the stage of comparing actual numbers, the dosage and dosage calculator pages walk through how weight-based adjustments typically work, and cycle length covers how long people typically stay on a given regimen before a break.

What does sirolimus cost, and does insurance cover it for longevity use?

Insurance will not cover sirolimus for longevity or anti-aging use, because there is no approved indication for it; insurers pay for FDA-approved, medically necessary uses, and off-label anti-aging prescribing does not qualify. If you're taking it for an approved transplant indication, coverage is a different, much more established conversation. Out of pocket, generic sirolimus tablets or oral solution cost meaningfully less than the brand Rapamune, though prices vary by pharmacy and dose. Because most longevity users are on a low weekly dose rather than a daily transplant dose, monthly costs for the drug itself are often modest compared to many other longevity interventions, but you should add in the cost of the consult (telehealth visit fees), any required labs, and pharmacy dispensing fees, which together usually matter more to your total spend than the pill cost alone. Beware sources selling "rapamycin" as an unregulated research chemical at a steep discount. You're not comparing the same product: no pharmacy quality control, no verified purity, and often no actual sirolimus content guarantee, since these products are explicitly sold outside drug manufacturing standards.

What are the real risks a prescriber should walk you through?

Three categories matter most for someone considering off-label sirolimus: immunosuppression, metabolic effects, and mouth ulcers, all documented in the FDA label at transplant doses and reported anecdotally at lower intermittent doses. Immunosuppression is mechanistic, not incidental. Rapamycin inhibits mTOR, a pathway central to T-cell proliferation and immune activation; the transplant indication exists because of this effect, not despite it. FDA's boxed warning for Rapamune states increased risk of "infections and possibly for the development of lymphoma and other malignancies, particularly of the skin" at continuous therapeutic doses ^[1]. Whether intermittent, low, weekly longevity dosing carries a meaningfully smaller risk is biologically plausible and supported by some mouse immune-function data, but is not established in humans by a completed trial. Metabolic effects include increases in fasting glucose, triglycerides, and total cholesterol, seen consistently in the transplant literature ^[1] and reported often enough in longevity users that a baseline and follow-up lipid panel plus glucose check is standard practice among careful prescribers. Mouth ulcers (stomatitis) are common enough that most longevity protocols discuss them upfront, usually resolving with dose timing changes or brief interruption rather than requiring discontinuation. None of this makes the drug unusable, but it does make self-directed dosing without monitoring a genuinely bad idea, more than an overcautious one.

Can you get sirolimus through a compounding pharmacy instead?

Sirolimus itself is a manufactured, FDA-approved generic drug (and brand Rapamune), not typically a compounded product, so most legitimate telehealth and clinic prescriptions get filled at regular pharmacies dispensing standard generic tablets or oral solution rather than through compounding. Compounding pharmacies do sometimes prepare custom formulations (for example, adjusted concentrations or alternative delivery methods) under a valid prescription, regulated at the state level by state boards of pharmacy and, for larger-scale "503B" outsourcing facilities, by FDA under the Drug Quality and Security Act, codified in relevant part at 21 U.S.C. 353b . But routine longevity dosing rarely needs anything compounded since standard tablet strengths (0.5 mg, 1 mg, 2 mg) and the oral solution already allow the flexible weekly dosing most protocols use. If a source claims sirolimus is only available compounded, that's usually a signal they're operating in the unregulated research-chemical space rather than dispensing the real, FDA-regulated drug. For anything involving actual injectable preparation or reconstitution steps, which some analog longevity compounds require but sirolimus tablets typically don't, see how to reconstitute Sirolimus Rx, how to inject, and injection sites for the mechanics, though most oral sirolimus users never need any of this.

What should you ask before choosing a telehealth prescriber?

Ask whether the platform requires baseline labs, whether a licensed physician actually reviews your case individually, which pharmacy fills the prescription, and what ongoing monitoring looks like. A legitimate service should answer all four clearly and specifically, not vaguely. Watch for these honest yellow flags: no labs requested at any point, no named prescribing physician, vague claims that sirolimus is "proven" to extend human lifespan (it is not, per the missing-trial problem discussed above), or pressure to buy a multi-month supply before a first consult happens. None of these automatically means fraud, but each one is a real reason to ask more questions before paying. A reasonable service will also be upfront that this is off-label use, will document that in your consult record, and will tell you plainly that the mouse data, while strong, hasn't been confirmed in a completed human lifespan trial. If a platform won't say that plainly, that's the biggest flag of all.

Frequently asked questions

Do you need a prescription for sirolimus in the US?

Yes, always. Sirolimus (Rapamune, generic sirolimus/rapamycin, Fyarro, Hyftor) is a prescription-only drug under FDA regulation with no OTC or supplement pathway. Anyone selling it without a prescription requirement is either operating outside drug law or selling an unregulated "research chemical" version with no guaranteed purity or dose.

Is rapamycin the same thing as sirolimus?

Yes. Rapamycin is the generic chemical name for the compound isolated from Streptomyces hygroscopicus; sirolimus is the official US Adopted Name used on prescription labels and by FDA. Rapamune is the original brand name. There's no meaningful legal or pharmacological difference that would let one be sold without a prescription and the other require one.

Can any doctor legally prescribe sirolimus for anti-aging?

Yes, any licensed physician can prescribe an FDA-approved drug off-label based on clinical judgment; that's legal in the US. What's uncommon is finding a doctor familiar with the longevity dosing literature and willing to do so, which is why telehealth longevity platforms and specialty clinics have become the main access route.

Has the FDA approved sirolimus for longevity or anti-aging?

No. FDA has approved sirolimus only for kidney transplant rejection prophylaxis, and separately as Fyarro for a rare cancer (PEComa) and Hyftor for tuberous-sclerosis-related facial angiofibroma. There is no FDA-approved indication, label, or dosing guidance for aging, lifespan extension, or anti-aging use.

What is the strongest evidence that rapamycin extends lifespan?

The NIA Interventions Testing Program found rapamycin extended median mouse lifespan by roughly 23% in males and 26% in females in its original 2009 cohort, later replicated at lower doses and even when started late in life. It's the strongest animal aging data of any longevity compound, but no completed human lifespan trial exists.

Why hasn't there been a human trial proving rapamycin extends human lifespan?

Human lifespan trials would take decades and enormous cohorts to detect a mortality effect, which is prohibitively expensive and slow to fund. Current human research (like the PEARL trial and earlier immune-function studies) focuses on safety, biomarkers, and short-term outcomes like vaccine response, not survival, leaving the core longevity claim unconfirmed in humans.

What are the real side effects of low-dose sirolimus?

Mouth ulcers (stomatitis), elevated cholesterol and triglycerides, elevated blood glucose, and immunosuppression are the most commonly reported effects, drawn from transplant-dose data and longevity-user reports. Immunosuppression is mechanistic to how the drug works, so any use, including low intermittent dosing, carries some degree of infection risk that a prescriber should monitor.

Does insurance cover sirolimus for longevity use?

No. Insurance covers FDA-approved, medically necessary indications like transplant rejection prophylaxis, not off-label anti-aging use. Longevity users pay out of pocket for the drug, the prescribing consult, and any required labs, though the drug itself (generic sirolimus at low weekly doses) is often the smallest part of that total cost.

What labs should be checked before and during sirolimus use?

Most careful prescribers check fasting lipid panel, fasting glucose or HbA1c, complete blood count, and kidney function before starting, then recheck periodically. This monitors for the known metabolic and blood-count effects seen in transplant-dose data. A service that prescribes with zero lab requirement is skipping a real safety step, not simplifying one.

Is buying rapamycin as a 'research chemical' legal and safe?

It exists in a legal gray area (sold "not for human use" to avoid drug regulation) but is not a safe substitute for a real prescription. There's no pharmacy quality control, no verified dose accuracy, and no clinical oversight, meaning you can't be sure what's actually in the product or whether it's dosed correctly.

How is longevity dosing of sirolimus different from the transplant dose?

Transplant dosing is continuous and daily (typically a 6 mg loading dose then 2 mg daily per the Rapamune label) to maintain constant immunosuppression. Off-label longevity protocols typically use intermittent once-weekly dosing, often in the 3 to 10 mg range depending on body weight, based on the theory that pulsing preserves benefits while limiting chronic immune suppression, though no large human trial has confirmed an optimal dose.

Can a compounding pharmacy make sirolimus without a prescription?

No. Compounding pharmacies still require a valid prescription from a licensed prescriber; they're regulated by state boards of pharmacy and, for larger facilities, by FDA under the Drug Quality and Security Act. Compounding isn't typically needed for sirolimus anyway, since standard manufactured tablets and oral solution already support flexible weekly dosing.

Sources

1. FDA, Hyftor approval information: FDA-approved Hyftor (topical sirolimus gel) for facial angiofibroma in tuberous sclerosis complex
2. Harrison DE et al., Nature, 2009: Rapamycin extended median lifespan by approximately 23% in male and 26% in female mice in the NIA Interventions Testing Program
3. National Institute on Aging, Interventions Testing Program: ITP has replicated rapamycin lifespan extension across multiple cohorts, doses, and start ages
4. Mannick JB et al., Science Translational Medicine, 2014: mTOR inhibition with RAD001 improved influenza vaccine response in elderly volunteers
5. 21 U.S.C. 353b, Drug Quality and Security Act, outsourcing facilities: Federal law governing regulation of compounding outsourcing facilities under the Drug Quality and Security Act